Bharat biotech News

The most prevalent AESIs in adolescents included new-onset skin and subcutaneous disorders (10.5 per cent) Serious AESI, which included stroke and Guillain-Barre syndrome, was reported in one per cent of individuals Recently, AstraZeneca admitted in the UK High Court about a rare risk of blood clot disorder due to its Covid vaccine

Nasal Covid-19 Vaccine: The first intranasal Covid-19 vaccine 'Incovac' developed in the country will be started from January 26. It has been made by Swadeshi Bharat Biotech.

This booster dose helps to boost the primary immunity of any person. There are specific reasons for these drops in the nose. It is possible to prevent the virus at the initial moment.

According to the Union Health Ministry, an emergency response mock drill will be conducted at hospitals across the country from December 27 in view of a spike in Covid cases in some countries. 

Govt terms report on approval for Covaxin due to political pressure as misleading and fallacious The reports further claimed that there were several irregularities in the three phases of the clinical trials conducted for the vaccine

Another vaccine has been approved in the war against the corona epidemic. DCGI has approved Bharat Biotech's nasal vaccine for Corona. This will be the country's first nasal vaccine.

DCGI has given nod to India’s First Intranasal Covid vaccine for restricted emergency use The DCGI has approved Bharat Biotech's intranasal Covid vaccine This was confirmed by Union Health Minister Mansukh Mandaviya through a tweet

Bharat Biotech has completed phase III clinical trials for intranasal Covid vaccine The firm said that 'it has proven to be safe' BBV154 has been specifically formulated to allow intranasal delivery

Clinical phase III trials of the COVID-19 nasal vaccine have been completed by Bharat Biotech The company will submit its data with Drugs Controller General of India next month

Germany has cleared the Bharat Biotech’s Covaxin Now, fliers won’t need to show vaccination proof now from June 1 This was also confirmed by German Ambassador Walter J Lindner

A 'Single, variant proof Covid-19 vaccine is being developed by a global consortium Bharat Biotech will be part of this global consortium CEPI will provide USD 19.3 million for the vaccine project

Bharat Biotech has sought nod for conducting booster dose trials of Covaxin for 2-18 age group. So far 2,88,62,660 precaution doses to the eligible beneficiaries.

Covaxin is developed indigenously by the Bharat Biotech India and Japan acknowledged the progress in the ongoing projects in Bangladesh

The Hyderabad based Bharat Biotech`s anti-Covid Vaccine, Covaxin has been suspended by WHO under the Covax facility, announced the UN health body on Saturday, attributing it to deficiencies in manufacturing practices.

Bharat Biotech said there were no issues with its Covid-19 vaccine or its certification. The data available to WHO, indicate the vaccine is effective and no safety concern exists, informed Bharat Biotech.

The WHO said the Bharat Biotech vaccine is effective and no safety concerns exist, but the suspension of production for export will result in the interruption of Covaxin supply. 

The vaccine maker, in a press release, said Bharat Biotech will focus on pending facility maintenance, process and facility optimisation activities for the coming period.

There are 33 vaccines all over the world Earlier this month, DCGI's granted approval to Bharat Biotech's nasal vaccine trial

Bharat Biotech has received approval for phase 3 clinical trials of intranasal vaccine. Intranasal vaccine can be easily administered.

The study was conducted at the Emory Vaccine Center in Atlanta based on blood serum collected from 13 individuals, 28 days after their booster shot, the Bharat Biotech said.